

Content available at: <https://www.ipinnovative.com/open-access-journals>

IP International Journal of Medical Microbiology and Tropical Diseases

Journal homepage: <https://www.ijmmttd.org/>

Review Article

The latest news for May 2022 all you need to know on monkeypox

Dheeraj Makkar^{1,*}

¹Dept. of Orthopedics, NC Medical College and Hospital, Panipat, Haryana, India



ARTICLE INFO

Article history:

Received 02-06-2022

Accepted 18-07-2022

Available online 06-09-2022

Keywords:

Monkeypox
Prevention
Treatment
Endemic
Transmission

ABSTRACT

Monkeypox virus was named so because of its detection in monkeys in 1958. It belongs to the same family as smallpox and chickenpox viruses. There had been numerous outbreaks of this malady initially in the African continent and other parts of the world. The simultaneous spread in nineteen countries in 2022 has raised some serious concerns.

Monkeypox is no more a rare disease and has the potential for bioweapon use. We discuss the various ways to prevent its spread, treatment options available, diagnosis, and differentiation from other closely related diseases. We also discuss if the present outbreak could be a bioattack or if this disease is here to stay.

The literature suggests that we can effectively manage Monkeypox because of the availability of drugs and vaccination against smallpox. There is also a need for active surveillance against the new resistant recombinant viral strains. The possibility of this outbreak being a bioattack seems remote, although there are questions about the transmission which still need to be answered.

This is an Open Access (OA) journal, and articles are distributed under the terms of the [Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License](https://creativecommons.org/licenses/by-nc-sa/4.0/), which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

For reprints contact: reprint@ipinnovative.com

1. Introduction

After Smallpox, Monkeypox (MPxV) has become a significant orthopoxvirus infection in humans. The Monkeypox virus belongs to Orthopoxvirus genus, which also contains Camelpox, Cowpox, Vaccinia, and Variola viruses.

Recent outbreaks of the MonkeyPox virus in Europe, Australia, and the US (Figure 1) have raised some strong questions. The spread across nineteen countries has indicated that it is not a rare disease anymore. This review tries to address the concerns caused by the recent outbreaks like biological warfare, will it become another COVID, and can it cause death. This article also emphasizes the historical perspective, diagnosis, prevention, treatment, alternative drugs to the mainstream medications, and differentiation between Smallpox, Monkeypox, and Chickenpox based on

their clinical presentation. Because the virus was isolated in monkeys, it was termed Monkeypox.

1.1. Historical perspective

One of the biggest paradoxes in the world of preventive healthcare was the eradication of smallpox but the advent of Monkeypox (MPX).¹

In 1958, monkeypox was first documented in Denmark due to a pustular infection in a troop of Singapore-imported monkeys.² On September 1, 1970, a nine-month-old boy was hospitalized at the Basankusu Hospital in the Democratic Republic of the Congo as the first documented MPXV incident in the medical literature.³ The youngster was the only one infected in the family.

The patient's relatives reported that they sometimes consumed monkeys as gourmet but could not recollect cooking one in the past month. They were also unsure whether the youngster had recently been in contact with

* Corresponding author.

E-mail address: makkardheeraj@gmail.com (D. Makkar).

a monkey. The analysis revealed that the infant was the sole family member who had not received the smallpox vaccination.

Later six more cases of monkeypox were reported between October 1970 and May 1971 in Liberia, Nigeria, and Sierra Leone.³

WHO confirmed 54 occurrences between 1970 and 1979 (20,30,61). Breman et al. described 47 of those fifty-four cases.⁴

In 1980 the Global Commission classified MPX for the Certification of Smallpox Eradication as the most significant orthopoxvirus illness in men in the post-smallpox era.⁵

Historically, monkeypox is confined to the environment of tropical rainforests. In 2005, 49 instances were documented in Sudan outside the rainforests for the first time. Those patients recovered without any fatalities.

1.2. 2003 U.S. outbreak

A little girl developed fever and redness after being attacked by a prairie dog during a trade fair near Milwaukee on May 11, 2003.⁶ As of June 20, 2003, 71 cases of monkeypox had been documented in the US utilizing electron microscopy and serologic testing. These incidents have been linked to Gambian pouched rats brought from Accra, Ghana, in April 2003 by a Texas-based dealer of exotic animals. It was the first outbreak of Monkey-pox in the US, and there were no fatalities.⁷

1.3. 2017–2019 Nigeria outbreak

According to reports, monkeypox has spread over Southeast and Southern Nigeria, including numerous states in the Southwestern regions of Nigeria. The outbreak began in September 2017 and continues in various states through May 2019.⁸

1.4. 2018 United Kingdom cases

Two cases were confirmed in Blackpool, the patient and the medical worker who cared for the patient from Blackpool. On December 3, 2019, a patient traveling from Nigeria to the United Kingdom was detected with monkeypox in southwest England, marking the occurrence of a fourth case.

In September 2018, the United Kingdom identified the first-ever incident of monkeypox. It is suspected that the individual, a Nigerian national, caught monkeypox in Nigeria prior to arriving in the United Kingdom.

1.5. 2019 Singapore case

A 38-year-old Nigerian male who had come to attend a wedding was admitted to Singapore's National Centre for Infectious Diseases on May 8 after being diagnosed with monkeypox. He was the country's first recorded case. Consequently, 22 hotel staff were quarantined. [59] The

patient may be associated with the continuing epidemic in Nigeria.⁹

No cases were reported in 2020 due to the spread of Covid and Lassa fever.¹⁰ The Covid pandemic resulted in a lockdown and social distancing which may have contributed to minimal or no spread of the MonkeyPox Virus.

2. 2021 Cases

2.1. Uk cases

Public Health Wales confirmed three cases of monkeypox originating from the same family on May 24 in the United Kingdom. The Public Health department detected the index case on May 24, following a trip from Nigeria. The second and third incidents were reported on June 2 and June 24, respectively.¹¹

2.2. US case

A US returnee from Nigeria was tested with monkeypox on July 14 in the United States. Subsequently, the patient was hospitalized and treated with tecovirimat before being discharged 32 days later.¹²

2.3. 2022 outbreak

In May 2022, the UK Health Security Agency reported multiple incidents of monkeypox in London and northeast England. Both Portugal and Spain recorded numerous incidents during the same month.¹³

New York City is also investigating a suspected case, admitted to Bellevue Hospital in seclusion. (New York Investigating Possible Monkeypox Case - but How Much of a Threat Is It? n.d.)

On May 22 in Quebec, Canada, five documented cases and twenty additional suspect instances are currently being investigated.¹⁴

Two cases were verified in Australia on May 20, one in Melbourne and the other in Sydney. In the Melbourne case, a man in his 30s returned from London on May 16 and is currently hospitalized at Alfred Hospital. In the Sydney instance, a man in his forties has likewise returned from Europe and is isolating himself at home. Each patient exhibits modest symptoms.¹⁵

Public Health Wales and the Public Health Agency of Northern Ireland reported one case each on May 26, bringing the total number of patients in the United Kingdom to 90.¹⁶

2.4. Transmission

MPXV may transmit via animals-to-humans and humans-to-humans. Animal-to-human transfer, also known as zoonotic transmission, happens through close contact with or eating any of the biological virus hosts.^{17,18}

2.4.1. Human to Human transmission behaviors

An increased chance of contracting an MPXV illness can be attributed to the following behaviors:

1. Falling asleep in the same room/bed.
2. Having food in the same dish.

Drinking from the same cup as the primary patient.¹⁹

Kissing, assistance with toileting and cleanliness, and laundering garments were not significantly associated with contracting the virus.¹⁹

Transfer of virus among humans may occur via close contact during close sexual intimacy, such as oral, anal, and vaginal sex, hugging, massage, mutual masturbation, kissing, and embracing. Other methods of spread involve handling textiles and things during intercourse that were used by an individual infected with monkeypox, like beddings, towels, etc. More research is being carried out to find the transmission via semen and vaginal secretions.²⁰

Infection dissemination in hospitals has also been observed, whereas sexual transmission has been hypothesized for infected people with groin and pubic lesions.²¹ On May 25, 2022, the CDC asked homosexuals and bisexuals to be cautious considering sexual transmission as one of the means of its spread, especially among homosexuals.²²

Anne Rimoin and Raina MacIntyre hypothesize in Nature that the higher proportion of MSM infected is the consequence of inadvertent entry to the community, followed by sexual behavior representing "direct contact," as opposed to the virus itself being transferred sexually.²³

Hospital spread can be prevented through the vaccination of medical personnel and using standard precautions.

2.4.2. Animal to human transmission

Most of the research implies that MPXV enters the human population through encounters with infected wildlife, most likely through eating or handling infected meat.^{17,24} The studies also suggest that the main route of transmission is through cutaneous, mucocutaneous, or airborne droplets.

There was no significant danger connected with having pets in the home, discovering animal carcasses around the house, getting into contact with animal feces, being bitten or clawed by an animal, or catching or consuming wild animals according to Nolen et al.¹⁹

The case-control study by Nolen et al demonstrates that there was a link between sleeping on the floor and an increased risk of infection. Living in a house with a door, eating a duiker (an antelope), and cooking meat from wild animals were recognized as protective factors.¹⁹

Densely populated areas are more predisposed to the rapid spread of the virus. More people were afflicted with MPXV who had a ground-clearing within 500 m from their house. They had cleared the area for agricultural purposes, increasing their contact with animals.^{24,25}

Nolen et al. suggest that neither the hunters nor the individuals who prepare the meat but male students were more likely to introduce the virus into a family. The reason could be the lack of small pox vaccination in young children. Due to pre-existing antibodies, older persons may have been impacted to a lower extent than youngsters.¹⁹

2.4.3. Human to animal transmission

To date, no such case has been reported.

3. Types of Monkey Pox virus

There are two strains of the Monkey Pox Virus: the Congo Basin also called Central Africa and the West Africa clades. According to reports, the Congo Basin clade (Central Africa clade) is more aggressive than the West Africa lineages and contributes more to human-to-human transmission.²⁶ Table 1

3.1. Reservoirs

Apart from monkeys, several squirrel species like rope squirrels (*Funisciurus* spp), tree squirrels (*Heliosciurus* spp), Gambian rats (*Cricetomys* spp), elephant shrews, domestic pigs, sooty mangabey monkey and various mice and rats (*Graphiurus*, *Xerus*,) may serve as a reservoir for the MPXV. The seroprevalence study revealed that squirrels had the highest positivity rate of antibodies against Orthomyxovirus but no definitive reservoir has not been found.²⁸ Surprisingly, the most frequent animal seized in the traps around the affected individual's residences was a mouse (*Mus* sp.).^{18,24}

The virus transmission between mammalian species was established by inoculating a rabbit (family Leporidae) with the MonkeyPox virus following exposure to an infected prairie dog at a veterinary facility.²⁸ Table 2

3.2. Why now

Thirty years later, the incidence of human MPX in the same region appears to have markedly increased

The causes involve

1. Reduced vaccine-induced protection from the virus,³⁰
2. Significant social and population shifts have raised MPX vulnerabilities and the probability of severe disease in humans.³⁰ This happened due to heavy rains and floods which placed people and MPXV-infected animal hosts in close proximity.
3. Periodic military conflicts and associated financial deterioration have driven country populations to migrate for long durations far into the bushland. Consequently, it has disturbed conventional country life and enhanced reliance on hunting for survival, hence increasing contact with animal hosts of MPX.²

Table 1:

	Congo Basin Clade/Central Africa Clade (lineage) ²⁷	West Africa Clade (lineage) ²⁷
T-cell inhibition	Yes	No
Gene inhibiting complement enzymes	Present	Absent
Down-regulate Apoptosis	Yes	No
Silent Transcription genes involving host immunity	Yes	No

Table 2:

Reservoir Animals of Monkeypox
Rope Squirrels Figure 3
Gambian Rats (used to detect land mines in Africa) Figure 4
Tree Squirrels
Elephant Shrews Figure 5 (“Elephant Shrew,” 2022)
Domestic Pigs
Sooty Mangabey Monkeys Figure 6 ²⁹
Rabbits

- Malnutrition arising from economic constraints and immunodeficiencies such as HIV, organ transplantation, immunosuppressant drugs, and autoimmune diseases, has also led to the recurrence of MPVX.²
- The virus may evolve into a more virulent strain capable of person-to-person transfer and increases with each recurrence or an outbreak.⁴
- The suspension of routine poxviri⁴ immunization after eradicating poxvirus has decreased herd immunity. The lowered herd immunity increases the susceptibility to MPVX. \$
- Increased urbanization of forests by humans, rapid increase in trade, and consumption of wildlife also contribute to the illness.

3.3. Definition of a Monkeypox case²⁸

According to CDC Human monkeypox cases have been categorized into:

Suspect case, Probable case, and a Confirmed case. The criteria for the three cases are: Table 3

3.4. Clinical criteria

The clinical criteria are based on the signs and symptoms and have the following: Table 4

3.5. Epidemiological criteria

Following are the epidemiological criteria established by the CDC following the 2003 outbreak of Monkeypoxvirus in the United States. Any one of these constitutes a positive criterion. Table 5

3.6. Laboratory criteria

The laboratory criteria include one of the following: Table 6

3.7. Clinical features²⁷

Initial symptoms include fever, widespread malaise, headache, and weariness.

Lymphadenopathy: Lymph nodes that are enlarged are hard and occasionally painful.

Fever: Fever typically subsides on the day of or up to three days after the beginning of the rash.

Rash: Typically, the rash starts initially on the face and then rapidly spreads to the rest of the body. The characteristic lesions frequently manifest as macular, papular, vesicular, and pustular lesions.

Variable numbers of lesions may be seen on a particular subject.

Patients complain of swollen, hard, and painful skin until crusts form⁴. The emergence of a second febrile phase when skin lesions become pustular has been coupled with worsening the patient's physical state.

3.8. Complications²⁷

3.8.1. Pulmonary

Bronchopneumonia,
Vomiting or diarrhea

3.8.2. Neurological

- Encephalitis
- Sepsis

3.8.3. Eye complications

- Ocular infections
- Corneal scarring
- Permanent vision loss

Table 3:

Case	Criteria	Clinical Features	
Suspect Case	Epidemiological criteria	Fever or Unexplained rash and two more signs or symptoms onset of the first sign or symptom within 21 days of exposure	If both are present it is a suspect case
Probable Case	Epidemiological criteria	Fever AND Pustular rash with the onset of the first sign or symptom within 21 days of exposure	Both constitute a probable case
Confirmed case	Meets laboratory criteria		

Table 4:

Clinical Criteria
Fever
Rash: macular, papular, vesicular, or pustular; generalised or localised; discrete or confluent
Other , sweats, headache, backache, lymphadenopathy, sore throat, cough, and/or shortness of breath

Table 5:

Contact (living in a home, stroking or holding, or visiting a pet holding facility such as a pet store or veterinary clinic) to an exotic or wild mammalian pet (including prairie dogs, Gambian giant rats, and rope squirrels, among others to be assessed on a case-by-case basis) obtained on or after April 15, 2003, with clinical evidence of sickness (eg conjunctivitis, respiratory problems, and/or rash).
Contact an exotic or wild mammalian pet with or no clinical signs of illness that have been in touch with a monkeypox-infected animal or a human being in the same house or at the same animal holding facility
Skin-to-skin contact/Face to Face contact with a suspected, probable, or definite human case

Table 6:

Growth of MPV in culture
Detection of MPV DNA in a patient specimen using PCR.
Electron microscopy reveals virus structure compatible with an orthopoxvirus in the lack of contact with some other orthopoxvirus.
Immunohistochemical evidence of the existence of orthopoxvirus in tissue in the lack of contact with some other orthopoxvirus.

3.8.4. Mortality

Eleven percent is the mean case fatality rate of unvaccinated individuals; minors are frequently more susceptible to severe forms of sickness.

Mc Collum and Damon observed substantial problems and repercussions in unvaccinated patients (74 percent) than in vaccinated patients (39.5 percent).²⁷

3.9. Differentiation from other poxviruses

Comparison of clinical features between human monkeypox, smallpox, and chickenpox (modified from Breman and Henderson)³¹Table 7

3.10. Diagnosis

Various diagnostic modalities used for detection of Monkey Pox Virus are:

Diagnostic tests are most successful when combined with clinical and epidemiologic information, such as a patient's immunization history. Lesion exudates on a swab or crust specimens continue to be among the best and least invasive acute patient specimens. Real-time polymerase chain reaction (PCR) is the most accurate diagnostic; however conventional techniques such as viral culture, Immunohistochemistry, and Electron microscopy can also be employed. The table below summarizes the diagnostic tests. Table 8

Table 7:

Disease Characteristics	Monkey Pox	Small Pox	Chicken Pox
History Recent contact with exotic animal Recent exposure to a patient with vesicular rash Previous vaccination against smallpox	Yes May Be No (Positive in 10 to 15 percent cases)	No Yes Rare	No Yes Yes
Incubation period Prodromal phase	7 to 17 days Yes (1-4 days)	7 to 17 days Yes(1-4 days)	10 to 21 days Yes (0-2 days)
Physical Examination Prodromal fever Malaise Fever Lymphadenopathy Headache	Yes Yes Between 38.5 ⁰ –40.5 ⁰ C Yes Yes Centrifugal Superficial Monomorphic* (80%) Pleomorphic (20%) 22-24 day Yes Umbilicated	Yes Yes Often more than 40 ⁰ C No Yes Centrifugal Deep Monomorphic 14-21 days Yes Umbilicated	Yes Yes Usually less than 38.8 ⁰ C N Yes o Centripetal Superficial Pleomorphic** 6-14 days Rare Dew Drop
Skin lesions Distribution of skin lesions Depth of skin lesions Evolution of skin lesions Desquamation of skin lesions Involvement of palms and soles The appearance of lesions (Figures 7,8,9)			
Complications Encephalitis Pneumonitis Ocular complications Secondary Soft tissue infections	Less than 1% Yes up to 12% Yes up to 5% Yes	Less than 1% Possible Yes up to 9% Yes	Less than 1% Yes up to 16% None Yes
Diagnosis DNA PCR Electron Microscopy Culture Possible Serology	Monkeypox Virus Pox Virus (Figure2) Yes Monkey Pox and Orthopox antibodies present	Variola Virus Pox Virus Yes Small Pox, Orthopox antibodies present	Varicella Zoster Virus Herpes Virus No Varicella antibodies present

*Monomorphic: Lesions are in a single stage of development while progressing.

**Pleomorphic: Lesions in different stages of their development while progressing.

Table 8:

Test	Advantage	Disadvantage
Viral Culture	<ul style="list-style-type: none"> Highly specific 	Takes several days
Electron Microscopy	<ul style="list-style-type: none"> Can be performed on different specimens from the same patient biopsy, scab, and vesicular fluid. 	Needs specialized equipment and skilled technicians
Immunohistochemistry	<ul style="list-style-type: none"> Can be used in biopsy to detect antigens quickly 	Nonspecific
DNA PCR	<ul style="list-style-type: none"> Can detect active disease Highly specific 	Expensive
Orthopoxvirus IgG antibodies	<ul style="list-style-type: none"> Detects previous exposure to Monkeypox virus Detects Small Pox Vaccination 	Non-specific Requires blood samples Requires cold chain for blood samples
Orthopoxvirus IgM antibodies	<ul style="list-style-type: none"> Detects recent exposure to Monkeypox Virus 	Non-specific Requires blood samples Requires cold chain for blood samples
Tetracore Orthopox Biothreat Alert	<ul style="list-style-type: none"> Detects active disease from a skin lesion Can be performed at room temperature Does not require special training 	Less sensitive than PCR Non-specific

Table 9:

Smallpox vaccines	Advantages	Disadvantages	Route of Administration	Trade name	Availability
Live Small Pox (vaccinia virus)	Lesion over the vaccination site Long-term storage	Common side effects Headache, muscle pain, fever, fatigue, nausea Cannot be given to immunocompromised like AIDS, Organ transplants Cannot be given to people with atopic dermatitis, eczema Eye disease on steroids And pregnant females Cardiotoxic effects, Neurological, ocular side effects, and Steven Johnson Syndrome ³²	Percutaneous Single-dose (15 pricks with a two-pronged needle in quick succession after dipping it in an injection vial in an area of around 5mm)and reevaluate the site after 6-8 days ³³ Figure 10	ACAM2000(second-generation vaccines)	Licensed in the US
Attenuated vaccinia virus vaccine	<ul style="list-style-type: none"> • No lesion over the injection site Can be used in • Elderly subjects • Patients with organ transplants • Clinically immunocompromised patients like AIDS, taking steroids • Can also be used in atopic dermatitis and eczema • Safety experience in mass vaccination due to smallpox outbreaks has been established No-Risk of: <ul style="list-style-type: none"> • Erythema multiforme • Post-vaccinal encephalitis³⁴ 	Those allergic to the chicken protein, benzonase, and gentamicin, must not take Imvanex. Common side effects Headache, muscle pain, fever, fatigue, nausea, injection site reactions like redness, pain, hardness, itching Major side effects Cardiac (Casual relationship) Cannot be used under 18 years pregnant, and lactating ³⁴	The general population (including people with atopic dermatitis) and immunocompromised without vaccination against smallpox2 doses 0.5 ml subcutaneous injection With the second dose after 28 days of the first. Immunocompromised with vaccination against smallpox2 doses 0.5 ml subcutaneous injection With the second dose after 28 days of the first. General Population including those with atopic dermatitis with vaccination against smallpox Single-dose 0.5 ml subcutaneous injection ³⁵	Imvanex/MVA BN previously named Imvamune (second-generation vaccines)	The European Commission has permitted the vaccination of immunocompromised adults and the broader adult population. Maintained in the Strategic National Stockpile of the United States ²⁷
Attenuated vaccinia virus	Demonstrates a safer profile and fewer adverse reactions than ACAM2000.	The virus can potentially multiply in humans ²⁷	Single Dose	LC16m8 (Third generation vaccines)	Licensed for use in Japan.

Continued on next page

Table 9 continued

Live attenuated vaccine against Smallpox and Monkeypox produced from MVA BN/Imvanex	Cannot be used for Pregnant, breastfeeding, and adolescents less than 18 years Mild side effects like were redness (80.9%), pain (79.5%), induration (70.4%), swelling (67.2%), and itching (32.0%) at the injection site; mild systemic effects like fatigue (33.5%), headache (27.6%), muscle pain (21.5%), nausea (9.6%), chills (2%), and diarrhoea (2%). (0.7%), as well as fever (0.5 percent). ³⁶ Serious Adverse Reactions Cardiac side-effects, Crohn's disease, sarcoidosis, extraocular muscle paresis, and throat tightness ³⁶	Two doses 28 days apart	JYNNEOS
---	---	-------------------------	---------

Table 10:

Drug	Mechanism of Action	Trade Name	Route of administration	Side-Effects	Stage of Development
Cidofovir	Inhibits viral DNA polymerase	Vistide	Intra-venous	Causes renal damage Prevention of side effects: iv hydration and concurrent administration of Probenecid	Already to treat 1. AIDS patient with CMV retinitis 2. Molluscum Contagiosum infections
CMX-001 (Brincidofovir)	Prodrug of Cidofovir inhibits DNA Polymerase 25 times more efficacy than cidofovir ³	Tembexa	Oral	Does not have renal side-effects of Cidofovir Can cause Nausea, Vomiting, and Abdominal Pain ³⁷	In developmental stages against Ebola virus, CM virus Used to treat Small Pox ³⁷
ST-246 (Tecovirimat)	Inhibits release of intracellular virus	Tpoxx	Oral Less absorbed in fasted individuals ³⁸	CNS toxicity in dogs ³⁸	Health Canada approved oral Tecovirimat for the treatment of smallpox in adults and children weighing a minimum of 13 kilograms in December 2021. ³⁹ The US Strategic National Stockpile contains two million doses of tecovirimat. all pox infections. In January 2022, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) recommended approving Tecovirimat SIGA for the treatment of orthopoxvirus disease (smallpox, monkeypox, cowpox, and vaccinia complications) in adults and children weighing at least 13kg. ⁴⁰
Other drugs showing promising results					

Continued on next page

Table 10 continued

North-methanocarbothymidine ⁴¹	Releases active metabolite due to viral thymidine kinase	N-MCT	Used intraperitoneally during animal trial	Has an advantage Active against Tecovirimat/Brimcidifovir resistant virus strains	Under investigations in the US
NIOCH-14 ⁴¹	Prodrug of tecovirimat Easier to produce than Tecovirimat		Oral		Potential new drug as per WHO
KAY-2-41 ⁴¹	Better efficacy than Cidofovir but less than Brimcidifovir or Tecovirimat		Used intraperitoneally during animal trial		Under investigations
Ribavarin and Tiazofurin	IMP dehydrogenase inhibitor Ribavarin might be useful in combination with other drugs like Cidofovir ⁴²	Rebetol (Ribavarin) Tiazofurine	Ribavarin: Oral inhalation in children Oral in adults	Side effect Ribavarin: Teratogenic, Flu-like syndrome, depression suicidal tendency (when used with interferon for Hepatitis C) Tiazofurin: pleuro-pericarditis, Flu-like syndrome	Ribavarin: already used for Hepatitis C, Was previously used for Respiratory Syncytial Virus infection in children
C-ca3-Ado and C3-Npc ³	SAH (S-adenosylhomocysteine) hydrolase enzyme inhibitor				Not tested in humans due to potential toxicity(Potential Antiviral Therapeutics for Smallpox, Monkeypox, and Other Orthopoxvirus Infections - ScienceDirect, n.d.)

3.11. Treatment

Smallpox vaccines are derived from a fully clonal expansion vaccinia virus. These vaccinations do provide immunity against the Monkeypox virus to a considerable extent. Hence these can be utilized to protect against the Monkeypox virus. The vaccinations are not employed routinely in endemic locations due to concerns of severe unpleasant effects in a demographic with an impaired immune status. The table below summarizes some common side effects, route of administration, and availability of these vaccinations. Table 9

3.12. Alternatives to vaccination

Many medications have demonstrated promise as antiviral treatments for Orthopoxvirus species; Table summarises the route of administration, side effects, and the license of these medicines. Some of these medications are still under investigational status. Cidofovir and Brimcicidofovir act by inhibiting viral DNA Polymerase, while ST-246 prevents the intracellular virus from escaping the cell. Table 10

3.13. Prevention

CDC recommends a lot of measures to prevent the spread of the Monkeypox Virus. Some of the strategies for controlling infections with the monkeypox virus:

1. Segregate infected individuals from those who may be susceptible to infection.
2. Scrub your hands with soap and water or use a sanitizer containing alcohol after touching diseased animals or humans.
3. Try not to interact with animals that may be infected (including sick animals or dead animals in areas where monkeypox occurs).
4. Staying away from objects in touch with sick animals or people, like bedding or clothes. (Conventional washing machines, warm water, and detergent can eliminate the MonkeyPox virus.)
5. Utilize the proper personal protective equipment (PPE) when providing care to patients, including a gown, gloves, respirator, and eye protection.
6. Targeted vaccination of high-risk groups like health care workers who treat monkeypox patients and people who spend a lot of time around animal reservoir species in areas where the disease is common could be considered.¹

The routine measures of surveillance and locating cases in an endemic area are encountered a lot of challenges. Poor technology, lack of finances, sample gathering issues, and medical problems in detecting monkeypox illness are some of the difficulties experienced by monitoring systems.

3.14. Post-exposure prophylaxis for monkeypox (PEP)³⁵

According to the US Advisory Committee on Immunization Practices (ACIP), individuals exposed to Monkeypoxvirus should be examined by a medical professional. Medical interventions like post-exposure immunization should be decided in agreement with public health officials on case to case basis. The CDC recommends that the smallpox vaccine be administered within four days of contact to effectively avert the initiation of the disease, although it can be administered up to 14 days later. The CDC further recommends, based on ACAM2000, that vaccination administered within 14 days of contact may alleviate the disease manifestations but may not avoid the onset of disease.

3.15. Type of contact that determines post-exposure prophylaxis

Any close contact with a clinical Monkeypox patient, their bodily fluids, or possibly contagious objects (such as clothes or beds) without the use of personal protective equipment.

Another form of high-risk exposure involves inhaling dust or droplets while cleaning contaminated spaces; Sharps injuries caused by contaminated equipment or contaminated gloves.

The room inmates or those who have spent at least one night in the same apartment as the Monkeypox case during the infectious phase.

Non-high risk contacts include the Next passenger on an airplane, No direct contact within one meter of the infected case without personal protection equipment kit, and contact with bodily fluids through (Riedel, 2005) intact skin.

3.16. Can Monkeypox cause death?

In the majority of cases, the manifestations of monkeypox resolve on their own after a few weeks. However, in certain situations, they might cause medical issues and even fatality.

3.17. Susceptibility

Monkeypox may cause more severe symptoms and death in neonates, children, and individuals with underlying immunity deficiencies.

3.18. Could it be biological warfare?

The Centers for Disease Control and Prevention (CDC) in Atlanta has made a list of microbes and ailments that could be utilized as bioweapons. These illnesses are put into three groups based on how they can be used and how they affect public health. Smallpox is in group A, which means it, is easily spread from individual to individual and has a high death rate. Monkeypox is not mentioned in the

list of an organism capable of being used for bioterrorism. But some reports suggest that one country had contemplated deploying monkeypox as a biological attack.^{43,44}

Due to human-to-human transmission of monkeypox documented in the previous five years, it can be used as a bioweapon.⁴⁵ However, in the current situation, the possibility of a bio-attack seems remote. Traveling from endemic nations and contact with contaminated animals aren't thought to be causes of any of the recorded incidents so far (as of May 2022) which might raise a suspicion of Monkeypox being used as a bioweapon.

3.19. Recommendations to prevent such outbreaks in the future (Rimoin & Graham, 2011)

The questions of whether or not to conduct field trials for vaccines and implement vaccination to control MPX in endemic regions will need to be answered periodically by the appropriate stakeholders for each affected region. The authors suggest that the current actions should be taken to inform these decisions:

1. Monitor endemic places for tracking disease occurrence, intensity and rate of person-to-person transmission, and changes in distribution pattern.
2. Identify the alterations linked with transmissibility or virulence of the Monkeypox virus in the genomic pattern.
3. Establish definite intermediate hosts as well as animal reservoirs. A human immunization program may not help prevent the transmission of MPX. The mobility of animals may serve as a proxy for spreading the disease's geographic range.
4. Develop successful, economical treatment options.
5. There should be allocation of effective vaccines to the endemic regions by the developed countries after conducting a successful trial in the endemic area.

3.20. Future trends

Emerging new orthopoxviruses that cause diseases in humans, such as the Georgia Caucasus-identified Akhmeta virus and the 2015 discovery of the Alaska-pox virus add urgency to the need for expanded funds for monkeypox research.⁴⁶

4. Conclusion

MonkeyPox is no longer endemic to the African continent. Outbreaks in the past and in May 2022 have demonstrated that it is now a global problem. Newer economic treatment and preventive measures should be sought to tackle it more effectively. Measures should be adopted for frequent surveillance among animal reservoirs to prevent such outbreaks in the future. An increase in outbreaks can lead to a deadlier virus through genetic recombination. Therefore,

we need more stringent measures and outlines to prevent MonkeyPox from becoming another COVID or SmallPox.

5. Conflict of Interest

None.

6. Source of Funding

We did not receive any specific support from funding agencies in the public, commercial, or not-for-profit entities.

References

1. Rimoin AW, Graham BS. Whither monkeypox vaccination. *Vaccine*. 2011;29(4):60–4. doi:10.1016/j.vaccine.2011.09.004.
2. Simpson K, Heymann D, Brown CS, Edmunds WJ, Elsgaard J, Fine P, et al. Human monkeypox – After 40 years, an unintended consequence of smallpox eradication. *Vaccine*. 2020;38(33):5077–81. doi:10.1016/j.vaccine.2020.04.062.
3. Alakunle E, Moens U, Nchinda G, Okeke MI. Monkeypox Virus in Nigeria: Infection Biology, Epidemiology, and Evolution. *Viruses*. 2020;12(11):1257. doi:10.3390/v12111257.
4. The current status of human monkeypox: memorandum from a WHO meeting. *Bull World Health Organ*. 1984;62(5):703–13.
5. Sklenovská N, Van Ranst M. Emergence of Monkeypox as the Most Important Orthopoxvirus Infection in Humans. *Front Public Health*. 2018;6:241. doi:10.3389/fpubh.2018.00241.
6. Anderson MG, Frenkel LD, Homann S, Guffey J. A case of severe monkeypox virus disease in an American child: emerging infections and changing professional values. *Pediatr Infect Dis J*. 2003;22(12):1093–6. doi:10.1097/01.inf.0000101821.61387.a5.
7. Medscape. <http://www.medscape.com/viewarticle/458671> (accessed May 24, 2022).
8. Bunge EM, Hoet B, Chen L, Lienert F, Weidenthaler H, Baer LR, et al. The changing epidemiology of human monkeypox-A potential threat? A systematic review. *PLoS Negl Trop Dis*. 2022;16(2):e0010141. doi:10.1371/journal.pntd.0010141.
9. Yong SEF, Ng OT, Ho ZJM, Mak TM, Marimuthu K, Vasoo S, et al. Imported Monkeypox, Singapore. *Emerg Infect Dis*. 2020;26(8):1826–30. doi:10.3201/eid2608.191387.
10. Nigeria Centre for Disease Control." <https://ncdc.gov.ng/> (accessed May 24, 2022).
11. Communicable disease threats report, 27 June-3 July 2021, week 26," European Centre for Disease Prevention and Control, Jul. 02, 2021. <https://www.ecdc.europa.eu/en/publications-data/communicable-disease-threats-report-27-june-3-july-2021-week-26> (accessed May 24, 2022);.
12. A Case of Monkeypox in a Returned Traveler." <https://www.reliasmedia.com/articles/149360-a-case-of-monkeypox-in-a-returned-traveler> (accessed May 24, 2022).
13. Portugal identifies five monkeypox infections, Spain has 23 suspected cases | Reuters." <https://www.reuters.com/business/healthcare-pharmaceuticals/portugal-identifies-five-monkeypox-infections-spain-has-eight-suspected-cases-2022-05-18/> (accessed May 24, 2022).
14. Ross S, Lofaro J. Five monkeypox cases have been confirmed in Quebec as Canada eyes vaccines. *Montreal*. 2022; Available from: <https://montreal.ctvnews.ca/five-monkeypox-cases-have-been-confirmed-in-quebec-as-canada-eyes-vaccines-1.5910246>(accessedMay24,2022).
15. "Monkeypox confirmed in Melbourne and Sydney - ABC News." <https://www.abc.net.au/news/2022-05-20/monkeypox-case-in-sydney-and-melbourne/101084864> (accessed May 24, 2022).
16. "Monkeypox cases confirmed in England – latest updates," GOV.UK. <https://www.gov.uk/government/news/monkeypox-cases-confirmed-in-england-latest-updates> (accessed May 27, 2022).

17. Beer EM, Rao VB. A systematic review of the epidemiology of human monkeypox outbreaks and implications for outbreak strategy. *PLoS Negl Trop Dis*. 2019;13(10):e0007791. doi:10.1371/journal.pntd.0007791.
18. Pal M, Mengstie F, Kandi V. Epidemiology, Diagnosis, and Control of Monkeypox Disease: A comprehensive Review. *Am J Infect Dis Microbiol*. 2017;5(2). doi:10.12691/ajidm-5-2-4.
19. Nolen LD. Introduction of Monkeypox into a Community and Household: Risk Factors and Zoonotic Reservoirs in the Democratic Republic of the Congo. *Am J Trop Med Hyg*. 2015;93(2):410–5. doi:10.4269/ajtmh.15-0168.
20. “U.S. Monkeypox 2022: Situation Summary | Monkeypox | Poxvirus | CDC.” <https://www.cdc.gov/poxvirus/monkeypox/response/2022/index.html> (accessed May 29, 2022).
21. Ogoina D, Izibewule JH, Ogunleye A, Ederiane E, Anebonam U, Neni A, et al. The 2017 human monkeypox outbreak in Nigeria-Report of outbreak experience and response in the Niger Delta University Teaching Hospital. *PLoS One*. 2019;14(4):e0214229. doi:10.1371/journal.pone.0214229.
22. Kimball S. CDC officials sound alarm for gay and bisexual men as monkeypox spreads in community,” CNBC, May 23, 2022. <https://www.cnbc.com/2022/05/23/cdc-officials-sound-alarm-for-gay-and-bisexual-men-as-monkeypox-spreads-in-community-.html> (accessed May 26, 2022).
23. “Monkeypox goes global: why scientists are on alert - PubMed.” <https://pubmed.ncbi.nlm.nih.gov/35595996/> (accessed May 27, 2022).
24. Hutin YJ, Williams RJ, Malfait P, Pebody R, Loparev VN, Ropp SL, et al. Outbreak of human monkeypox, Democratic Republic of Congo. *Emerg Infect Dis*. 1996;7(3):434–8. doi:10.3201/eid0703.010311.
25. Khodakevich L, Jezek Z, Messinger D. Monkeypox virus: ecology and public health significance. *Bull World Health Organ*. 1988;66(6):747–52.
26. Kabuga AI, Zowalaty ME. A review of the monkeypox virus and a recent outbreak of skin rash disease in Nigeria. *J Med Virol*. 2019;91(4):533–40. doi:10.1002/jmv.25348.
27. McCollum AM, Damon IK. Human Monkeypox. *Clin Infect Dis*. 2014;58(2):260–7. doi:10.1093/cid/cit703.
28. Giulio DBD, Eckburg PB. Human monkeypox: an emerging zoonosis. *Lancet Infect Dis*. 2004;4(1):15–25. doi:10.1016/s1473-3099(03)00856-9.
29. Santiago ML. Simian immunodeficiency virus infection in free-ranging sooty mangabeys (*Cercocebus atys atys*) from the Taï Forest, Côte d’Ivoire: implications for the origin of epidemic human immunodeficiency virus type 2. *J Virol*. 2005;79(19):12515–27.
30. Robert H. Ebert Memorial Lecture Emerging and Re-emerging Infectious Diseases: The Perpetual Challenge,” Milbank Memorial Fund. <https://www.milbank.org/publications/2005-robert-h-ebert-memorial-lecture-emerging-and-re-emerging-infectious-diseases-the-perpetual-challenge/> (accessed May 24, 2022).
31. Breman JG, Henderson DA. Diagnosis and management of smallpox. *N Engl J Med*. 2002;346(17):1300–8. doi:10.1056/NEJMra020025.
32. ACAM2000 (Smallpox (Vaccinia) Vaccine, Live): Uses, Dosage, Side Effects, Interactions, Warning.” <https://www.rxlist.com/acam2000-drug.htm> (accessed May 27, 2022).
33. Vaccine Administration | Smallpox | CDC,” Feb. 19, 2019. <https://www.cdc.gov/smallpox/clinicians/vaccination-administration2.html> (accessed May 27, 2022).
34. EMA, “Imvanex,” European Medicines Agency, Sep. 17, 2018. <https://www.ema.europa.eu/en/medicines/human/EPAR/imvanex> (accessed May 27, 2022). 2018;.
35. Recommendations for the use of preand post-exposure vaccination during a monkeypox incident; 2022. Available from: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1099624/Recommendations-for-pre-and-post-exposure-vaccination-during-a-monkeypox-incident-22August2022.pdf.
36. C. for B. E. and Research, “JYNNEOS,” FDA, Jun. 2021, Accessed: May 28, 2022. [Online]. Available: <https://www.fda.gov/vaccines-biologics/jynneos>.
37. C. for D. E. and Research, “FDA approves drug to treat smallpox,” FDA, Sep. 2021, Accessed: May 26, 2022. [Online]. Available: <https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-drug-treat-smallpox>.
38. Grosenbach DW, Jordan R, Hruba DE. Development of the small-molecule antiviral ST-246® as a smallpox therapeutic. *Future Virol*. 2011;6(5):653–71. doi:10.2217/fv.11.27.
39. Siga Technologies Inc (SIGA-Q) Quote - Press Release,” The Globe and Mail. Accessed: May 26, 2022. [Online]. Available: <https://www.theglobeandmail.com/investing/markets/stocks/SIGA-Q/pressrelease/s/6434674/>.
40. EMA, “Summary of product characteristics,” European Medicines Agency. <https://www.ema.europa.eu/en/glossary/summary-product-characteristics> (accessed May 26, 2022).
41. “Drug Development against Smallpox: Present and Future - PubMed.” <https://pubmed.ncbi.nlm.nih.gov/31932370/> (accessed May 29, 2022).
42. “Potential antiviral therapeutics for smallpox, monkeypox and other orthopoxvirus infections - ScienceDirect.” <https://www.sciencedirect.com/science/article/abs/pii/S0166354202001961> (accessed May 29, 2022).
43. “Russia ‘planned to use monkeypox as a bioweapon’, report warned | Metro News.” <https://metro.co.uk/2022/05/20/russia-planned-to-use-monkeypox-as-a-bioweapon-report-warned-16680912/> (accessed May 27, 2022).
44. “Russia was planning to use monkeypox as bioweapon, claims ex-Soviet scientist - World News.” <https://www.wionews.com/world/russia-was-planning-to-use-monkeypox-as-bioweapon-claims-ex-soviet-scientist-480996> (accessed May 27, 2022).
45. Riedel S. Smallpox and biological warfare: a disease revisited. *Bayl Univ Med Cent*. 2005;18(1):13–20. doi:10.1080/08998280.2005.11928026.
46. Gigante CM, Gao J, Tang S, McCollum AM, Wilkins K, Reynolds MG, et al. Genome of Alaskapox Virus, a Novel Orthopoxvirus Isolated from Alaska. *Viruses*. 2019;11(8):708. doi:10.3390/v11080708.

Author biography

Dheeraj Makkar, Assistant Professor

Cite this article: Makkar D. The latest news for May 2022 all you need to know on monkeypox. *IP Int J Med Microbiol Trop Dis* 2022;8(3):183-195.